Latest Conference Articles

SLEEP 2026: Ashesha Mechineni, MD, discusses what the emerging pharmacotherapy pipeline means for clinicians.

Tirzepatide, nerve stimulation, and oral AD109 are reshaping OSA care as phenotyping replaces the one-size-fits-all CPAP default.

Patients with OSA who cannot tolerate CPAP may benefit from discussions about oral appliances, HNS, and other treatment options. Sairam Parthasarathy, MD, dives deeper.

SLEEP 2026: Virend Somers, MD, PhD, details how busy primary care physicians can address sleep in routine visits.

SLEEP 2026: GLP-related home sleep testing made up 44% of primary care referrals, but many studies were negative or suboptimal, according to a late-breaking abstract.

SLEEP 2026: Virend Somers, MD, of Mayo Clinic, outlines why sleep has been added to the AHA's Life’s Essential 8.

Laura B. Herpel, MD, reviews REFRESH trial data on once-nightly oxybate in narcolepsy, focusing on daytime function, stimulant reduction, and mental health.

SLEEP 2026: In an 8-week randomized trial, reishi mushroom extract reduced Insomnia Severity Index scores more than melatonin in adults with chronic insomnia.

Wearable sleep tracker use was linked to better sleep in patients with insomnia and COMISA, while OSA showed a divergent pattern warranting further study.

Mander highlights sleep as a modifiable dementia risk factor, emphasizing sleep apnea diagnosis and treatment to support brain health.

Emerging data link sleep disorder severity to Alzheimer's biomarker accumulation, with small CPAP studies suggesting partial biomarker reversibility with treatment.

Prenatal sleep expectations predicted postpartum sleep quality above parity and psychiatric history, with postpartum anxiety further worsening outcomes.

Pauline Maki, PhD, reviews data showing over half of elinzanetant's sleep benefit in postmenopausal women is independent of VMS reduction.

From behavioral therapy to NK3 receptor antagonists, Baker outlines an expanding toolkit for menopausal sleep disturbance.

Baker discusses menopause-related sleep disturbances and why early screening and individualized treatment are critical in primary care.

High-risk rural patients were less likely than urban patients to be referred for obstructive sleep apnea evaluation in primary care.

New research suggests EDS combined with prolonged sleep-onset latency is linked to 3x greater risk of incident hypertension and 2x greater risk of prevalent hypertension.

AD109 reduced apnea-hypopnea index versus placebo in a phase 3 trial of adults with OSA unable or unwilling to use CPAP.

Late-breaking SLEEP 2026 findings bring primary-care-ready insights on insomnia drugs, sleep apnea genetics, menopausal sleep, and GLP-1 links.

SLEEP 2026: Women with moderate-to-severe obstructive sleep apnea reported worse sleep, fatigue, anxiety, headaches, and nocturia than men.

ACOG 2026: CDC data show many pregnancy-related deaths may be preventable through better care coordination, access, and follow-up.

Despite waning direct impact of COVID-19, US pregnancy-related mortality remains higher than before the pandemic, driven by persistent cardiovascular, infectious, and hemorrhagic causes.

MR-100A-01 weekly contraceptive patch data will be presented ahead of an FDA decision on the investigational lower-estrogen product.

Highlights include time-efficient strategies for primary care clinicians to identify, assess, and treat GSM and other sexual health concerns during menopause.

ACOG 2026: Kathryn Miele, MD, discusses syphilis screening in pregnancy and how clinicians can reduce stigma around testing.

ACOG 2026: Kathryn Miele, MD, discusses syphilis titer interpretation, discordant results, partner treatment, and practical resources for primary care clinicians.

Highlights include clinical gaps in menopause care, postpartum prevention, cervical cancer screening, pregnancy-related infection, and GLP-1 RA exposure.

Pneumococcal vaccination in pregnancy remains underused in high-risk patients. Maria Marcos, MD, reviews new data, barriers to uptake, and practical vaccination steps for primary care.

Jill Liss, MD, outlines how updated evidence, risk stratification, and newer nonhormonal agents can help PCPs confidently manage VMS in everyday practice.

ACOG 2026: James A. Simon, MD, discusses off-label evidence for elinzanetant in breast cancer survivors on anti-estrogenic therapy.